Your Trusted Partner in Personal Injury & Workers' Compensation
Call Now: 904-383-7448(Code 1933, § 88-3112.3, enacted by Ga. L. 1977, p. 281, § 4; Ga. L. 2014, p. 683, § 2-3/HB 965.)
The 2014 amendment, effective April 24, 2014, added "and opioid antagonists" at the end of paragraph (a)(2). See Editor's notes for applicability.
- Ga. L. 2014, p. 683, § 2-1/HB 965, not codified by the General Assembly, provides:
"WHEREAS, Naloxone is an opioid antagonist developed to counter the effects of opiate overdose, specifically the life threatening depression of the central nervous and respiratory systems; and
"WHEREAS, Naloxone is clinically administered via intramuscular, intravenous, or subcutaneous injection; and
"WHEREAS, Naloxone is administered outside of a clinical setting or facility intranasally via nasal atomizer; and
"WHEREAS, the American Medical Association supported the lay administration of this life saving drug in 2012; and
"WHEREAS, similar Naloxone access laws have reversed more than 10,000 opioid overdoses by lay people in other states; and
"WHEREAS, the American Medical Association acknowledged that 'fatalities caused by opioid overdose can devastate families and communities, and we must do more to prevent these unnecessary deaths'; and
"WHEREAS, the National Institutes of Health found that Naloxone 'lacks any psychoactive or addictive qualities . . . without any potential for abuse . . . [and] medical side effects or other problematic unintended consequences associated with Naloxone have not been reported'; and
"WHEREAS, any administration of Naloxone to an individual experiencing an opioid overdose must be followed by professional medical attention and treatment."
Ga. L. 2014, p. 683, § 3-1/HB 965, not codified by the General Assembly, provides, in part, that Parts I and II of this Act shall apply to all acts committed on or after April 24, 2014.
Cited in Griesel v. Hamlin, 963 F.2d 338 (11th Cir. 1992).
No results found for Georgia Code 31-11-53.